| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Arcutis Biotherapeutics, Inc. (ARQT) has 13 insiders with recent SEC Form 4 filings, including 4 buys and 10 sells. ARQT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 740.5K | $19.48M | - | |
| Other | 150.2K | $3.95M | - | |
| Other | 127.6K | $3.36M | - | |
| Other | 120.2K | $3.16M | - | |
| CFO | 86.0K | $2.26M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 2, 2020 | Silverstein Jonathan | Director, 10% Owner | Buy | 496,000 | $25.00 | $12,400,000.00 | +10.6% | |
| Oct 1, 2020 | Welgus Howard G.61 | Director | Sale+OE | 2,200 | $27.65 | $60,828.86 | -0.6% | |
| Sep 29, 2020 | Watanabe Todd Franklin65 | President And CEO | Sale+OE | 3,000 | $30.00 | $90,000.00 | -0.5% | |
| Sep 29, 2020 | Smither John W65 | Chief Financial Officer | Sale+OE | 1,750 | $30.00 | $52,500.00 | -1.4% | |
| Sep 29, 2020 | Osborne David W76 | Chief Technical Officer | Sell | 15,000 | $30.00 | $450,000.00 | -5.4% | |
| Sep 29, 2020 | Watanabe Todd Franklin65 | President And CEO | Sale+OE | 3,000 | $30.00 | $90,000.00 | -0.5% | |
| Sep 1, 2020 | Welgus Howard G.61 | Director | Sale+OE | 2,200 | $24.38 | $53,643.26 | -1.2% | |
| Aug 3, 2020 | Welgus Howard G.61 | Director | Sale+OE | 2,800 | $25.63 | $71,764.28 | -0.9% | |
| Feb 4, 2020 | Frazier Life Sciences Viii, L.P. | 10% Owner | Buy | 500,000 | $17.00 | $8,500,000.00 | +5.0% | |
| Feb 4, 2020 | Heron Patrick J87 | Director, 10% Owner | Buy | 500,000 | $17.00 | $8,500,000.00 | +5.0% |